Securities and Exchange Commission
November 20, 2019
Page 2
Concurrently with the filing of the Registration Statement, the Company is hereby in this letter setting forth the Company’s responses to the comments contained in the letter from the staff of the Commission (the “Staff”) dated October 4, 2019. The Staff’s comments are repeated below in bold and are followed by the Company’s responses. Capitalized terms used but not otherwise defined herein have the meanings set forth in the Registration Statement.
To facilitate the Staff’s review, we are separately delivering to you today five courtesy copies of the Registration Statement, marked to show changes to the registration statement filed with the Commission on September 25, 2019, as well as two copies of the filed exhibits.
The Company respectfully advises the Staff that it plans to file the preliminary prospectus with the price range for the proposed offering on or about November 29, 2019, and to commence the road show on or about December 2, 2019. In addition, the Company plans to request that the Staff declare the effectiveness of the Registration Statement on or about December 12, 2019, and will file joint acceleration requests in time before the requested effective time. The Company would appreciate the Staff’s timely assistance and support to the Company in meeting the proposed timetable for the offering.
Amendment No. 1 to Form F-1 filed on September 25, 2019
Management
Directors and Executive Officers, page 162
1. | We note your disclosure that each of Messrs. Wei and Ge have agreed to serve as a director of the Company upon effectiveness of the registration statement. Please file the consent of these individuals as required by Securities Act Rule 436. |
In response to the Staff’s comment, the Company has revised the disclosure on page II-5 and filed the consents of the independent director appointees as exhibits 23.4 and 23.5.
Description of Share Capital
Shareholders Agreement , page 184
2. | With reference to Exhibit 4.5, please revise the disclosure on page 184 and elsewhere to clarify, if true, that SAIF IV Healthcare (BVI) Limited’s board representation rights do not terminate upon completion of the offering. |
In response to the Staff’s comment, the Company has revised the disclosure on page 184 to clarify that SAIF IV Healthcare (BVI) Limited’s board representation rights do not terminate upon completion of the offering.
Exhibits
3. | Please have counsel revise its Exhibit 5.1 opinion to remove the assumption in paragraph (d). Refer to Staff Legal Bulletin No. 19, Section II.B.3. Also, have counsel remove language in this opinion and in Exhibit 8.1 indicating that the opinion is in “Draft” form. |
In response to the Staff’s comment, the Company has revised exhibits 5.1 and 8.1 accordingly and re-submitted the exhibits.